Related Experiment Video
Updated: May 13, 2026
07:00
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
Published on: April 1, 2019
The relationship between coronary artery ectasia and eNOS intron 4a/b gene polymorphisms
Ahmet Ekmekçi1, Kazim Serhan Ozcan, Neslihan Abaci
1Department of Cardiology, Siyami Ersek Cardiovascular and Thoracic Surgery Centre, Istanbul, Turkey.
Acta Cardiologica
|March 6, 2013
Summary
The "a" type allele of the endothelial nitric oxide synthase (eNOS) gene may increase the risk of coronary artery ectasia (CAE). This genetic factor warrants further investigation in CAE pathogenesis.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
Background:
- Pathogenesis and genetics of coronary artery ectasia (CAE) remain largely unknown.
- Endothelial nitric oxide synthase (eNOS) gene intron 4a/b polymorphism is investigated as a potential factor in CAE.
Purpose of the Study:
- To investigate the association between eNOS gene intron 4a/b polymorphism and coronary artery ectasia.
- To explore the genetic underpinnings of CAE development.
Main Methods:
- Study included 30 patients with CAE and 30 controls with normal coronary arteries.
- Agarose gel electrophoresis was employed to determine eNOS gene polymorphisms.
- Coronary angiography was used for diagnosis and assessment of coronary artery disease (CAD).
Main Results:
- The "a" allele of the eNOS gene was significantly more frequent in patients with CAE compared to controls (P=0.027).
- While eNOS phenotypes differed between groups, statistical significance was not reached for all comparisons (P=0.08).
- Univariate analysis showed a correlation between eNOS polymorphism and CAE, which diminished after adjusting for confounders.
Conclusions:
- The presence of the "a" type allele of the eNOS gene may be associated with an elevated risk of developing coronary artery ectasia.
- Further research is needed to elucidate the role of eNOS gene polymorphism in CAE pathogenesis.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
02:32Exon Recombination
The evolution of new genes is critical for speciation. Exon recombination, also known as exon shuffling or domain shuffling, is an important means of new gene formation. It is observed across vertebrates, invertebrates, and in some plants such as potatoes and sunflowers. During exon recombination, exons from the same or different genes recombine and produce new exon-intron combinations, which might evolve into new genes.
Exon shuffling follows “splice frame rules.” Each exon has three reading...
Exon shuffling follows “splice frame rules.” Each exon has three reading...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
01:30Coronary Artery Disease I: Introduction
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...